Sackler, the producer of controversial opioid OxyContin, is reportedly facing financial challenges, with revenue expected to fall below $1bn in 2019 for the first time in 10 years. Contraction of the workforce, falling sales, and a mooted bankruptcy filing, as well as potential restructuring and opioid-related lawsuits across the US, are among the challenges faced by the company. Purdue, which is controlled by the Purdue Pharma family, is also thought to be facing a government investigation into fraud at affiliated entities. The pharmaceutical's core product, prescription painkiller OxyContin, is the subject of numerous lawsuits and is experiencing reduced sales.
Purdue Pharma, the producer of controversial opioid OxyContin, is reportedly facing financial challenges, with revenue expected to fall below $1bn in 2019 for the first time in 10 years. Contraction of the workforce, falling sales, and a mooted bankruptcy filing, as well as potential restructuring and opioid-related lawsuits across the US, are among the challenges faced by the company. Purdue, which is controlled by the Sackler family, is also thought to be facing a government investigation into fraud at affiliated entities. The pharmaceutical's core product, prescription painkiller OxyContin, is the subject of numerous lawsuits and is experiencing reduced sales.